Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of MEK Inhibitor MEK 162 Combined Sequentially With Gemcitabine-Oxaliplatin (GEMOX) in Patients With Advanced Biliary Cancer

NCT02105350 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02105350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02105350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of MEK Inhibitor MEK 162 Combined Sequentially With Gemcitabine-Oxaliplatin (GEMOX) in Patients With Advanced Biliary Cancer
Lead sponsor
University Health Network, Toronto
Phase
Phase 1
Overall status
Withdrawn
Start date
June 30, 2015
Completion date
June 30, 2015
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract carcinoma, gallbladder carcinoma